MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2018 International Congress

October 5-9, 2018. Hong Kong. Abstracts are presented on the 6th, 7th, and 8th.

View by Title View Sessions
View by Date
Jump to:  View All • a b c d e f g h i j k l m n o [p] q r s t u v w x y z
  • Pain is correlated with other motor and non-motor symptom in Parkinson’s disease

    Y. Liu, X.Y. Zhu, X.J. Zhang, S.L. Yang, T.Y. Feng, Y.C. Wu (Shanghai, China)

  • Palliative Virtual Home Visits for Atypical Parkinsonian Disorders (PVH-Park Study)

    M. Afshari, A. Butala, J. Guenther, A. Pantelyat, N. Galifianakis (San Francisco, CA, USA)

  • Pallidal and thalamic oscillations are associated with tic severity in patients with Tourette syndrome

    WJ. Neumann, J. Huebl, C. Brücke, R. Lofredi, A. Saryyeva, K. Müller-Vahl, J. Krauss, A. Kühn (Berlin, Germany)

  • Pallidal beta bursts in Parkinson’s disease and Dystonia

    R. Lofredi, WJ. Neumann, C. Brücke, J. Huebl, GH. Schneider, A. Kühn (Berlin, Germany)

  • Pallidotomy for Intractable Hemichorea in Sudden Hyperglicemic Pituitary Adenoma Patient

    Y. Tatang, M. Inggas (Jakarta, Indonesia)

  • Pallidotomy in dystonia –Experience from a tertiary care centre in a developing country

    K. Garg, M. Singh, V. Goyal, R. Sharma (New Delhi, India)

  • Papez circuit atrophy in Dementia with Lewy Bodies

    E. Matar, S. Wong, R. Tan, O. Piguet, M. Hornberger, J. Krill, J. Hodges, G. Halliday (Sydney, Australia)

  • Parallel evaluation of mutant huntingtin and neurofilament light in Huntington’s disease

    L. Byrne, F. Rodrigues, E. Johnson, E. De Vita, C. Czech, S. Schobel, R. Scahill, A. Heslegrave, H. Zetterberg, W. Wild (London, United Kingdom)

  • Paraneoplastic and neuronal surface antibodies in Parkinson’s disease and atypical parkinsonian disorders

    R. Constantinescu, C. Malmeström, D. Krýsl, D. Jons, M. Axelsson (Gothenburg, Sweden)

  • Parkinson-related CHCHD2 is necessary for oligomerization of ALS/FTD-related CHCHD10

    D. Narendra, X. Huang, B. Wu, Y. Liu, D. Nguyen, M. Marani (Bethesda, MD, USA)

  • Parkinson’s disease against the background of an essential tremor in people of Uzbek nationality

    R. Matmurodov, K. Khalimova, F. Odinayev (Tashkent, Uzbekistan)

  • Parkinson’s disease anxiety is associated with Lewy bodies in the Anterior Cingulate

    N. Fischer, J. Hinkle, K. Perepezko, G. Pontone (Baltimore, MD, USA)

  • Parkinson’s disease motor symptoms are linked to red nucleus volume and cerebellar metabolism

    A. Bonnet, R. Sanford, A. Riou, S. Drapier, F. Le Jeune, M. Vérin, D.L. Collins (Rennes, France)

  • Parkinson’s Disease Risk in Breast Cancer

    R. Mills-Joseph (Columbus, OH, USA)

  • Parkinson’s disease and palliative care

    A. Manna, L. Khanra (East Medinipur, India)

  • Parkinson’s Disease Psychosis Associated Comorbidities, and Mortality in the Medicare Population

    D. Weintraub, A. Willis, P. Torres, A. Shim, J. Norton, K. Liu, G. Demos (Philadelphia, PA, USA)

  • Parkinson’s disease-related non-motor features as risk factors for post-operative delirium in spinal surgery

    SY. Kang, KH. Kim, DA. Shim, SW. Choi, MJ. Son, YH. Sohn, PH. Lee (Hwaseong, Republic of Korea)

  • Parkinson’s disease, peripheral neuropathy, impaired gait, and the role of physiotherapy

    M. Alvarez (San Antonio, TX, USA)

  • Parkinsonism & Cognitive Dysfunction Severity Correlation in NPH with a Suggested Novel Phenotypic Subclassifcation of NPH

    A. Acharya, A. Biswas, S. Das (Kolkata, India)

  • Parkinsonism in Christianson Syndrome: A Unique Presentation of a Unique Syndrome

    S. Chandra, K. Rao, A. Ghosh, J. Ray, H. Northrup, E. Stimming (Houston, TX, USA)

  • Parkinsonism with rare sequence variants in VPS35 and FBXO7 genes associated with Lewy body pathology

    K. Mensikova, L. Tuckova, R. Vodicka, K. Kolarikova, T. Bartonikova, J. Ehrmann, R. Vrtel, P. Kanovsky (Olomouc, Czech Republic)

  • Paroxysmal kinesigenic dyskinesia successfully treated with lamotrigine –description of 2 cases

    E. Papuć, K. Rejdak (Lublin, Poland)

  • Paroxysmal multifocal dystonia with hemiplegic migraine possibly related to novel CACNA1A mutation

    A. Hannoun, K. Smith (Worcester, MA, USA)

  • Partial depletion of peripheral M1 macrophages ameliorates the neuroinflammation and dopaminergic neuronal death in the brain of a MPTP-induced mouse model of PD

    A. Yan, Y. Zhang, J. Lin, L. Song, X. Wang, Z. Liu (Shanghai, China)

  • PASSPORT, An Ongoing Phase 2 Study in Patients with PSP– Baseline Characteristics

    T. Dam, A. Boxer, L. Golbe, G. Höglinger, H. Morris, I. Litvan, J.C. Corvol, A. Lang, C. Bechtold, I. Qureshi, M. Grundman, B. Han, J. O'Gorman, T. Olsson, S. Budd Haeberlein (Cambridge, MA, USA)

  • Pathophysiologic insights into ataxia and spasticity through structural imaging of a spinocerebellar ataxia type 7 (SCA7) cohort

    J. Parker, S. Merchant, S. Horovitz, M. Hallett (Bethesda, MD, USA)

  • Patient and Caregiver Experience With Pantothenate Kinase-Associated Neurodegeneration

    H. Jinnah, W. Lenderking, A. Collins, M. Escolar, T. Klopstock, M. Kruer, A. Videnovic, A. Robichaux-Viehoever, L. Swett, D. Revicki, R. Bender, R. Marshall (Atlanta, GA, USA)

  • Patient and Provider Experiences and Attitudes toward Rytary

    S. Horn, D. Coughlin, J. Chou, F. Wang, M. Stacy, R. Dolhun, C. Kopil, N. Amondikar, A. Deik, H. Sarva (Philadelphia, PA, USA)

  • Patient Experience of Parkinson’s Disease Psychosis Management

    P. Schmidt, F. Cubillos, A. Diaz, P. Wiener, S. Metz, N. Romero, A. Shim, D. Fredericks (Miami, FL, USA)

  • Patient Perceptions of Dopaminergic Therapy Withdrawal in Parkinson’s disease

    N. Kukreti, P. Trujillo-Diaz, N. Van Wouwe, D. Claassen (Nashville, TN, USA)

  • Patient Perspective in Multiple System Atrophy

    A. Mahajan, Z. Mari (Detroit, MI, USA)

  • Patient with secondary dystonia treated with internal globus pallidus deep brain stimulation (GPi-DBS), 2 years results: A case report

    O. Morsi, AE. Baidez, J. Jimenez, J. Lopez, G. Valero, B. Cuartero, M. Felipe, R. Carrasco, J. Zamarro (Murcia, Spain)

  • Patient’s Choice of Device-Based Treatments in Parkinson’s Disease

    M. Kuzu Kumcu, S. Tezcan Aydemir, Ç. Ulukan, B. Bakırarar, C. Akbostancı (Ankara, Turkey)

  • Patients experiencing peak-dose dyskinesia use re-distribution of involuntary movement amplitude throughout their body to minimize the functional impact of dyskinesia

    K. Lebel, E. Goubault, S. Bogard, C. Duval (Montréal, QC, Canada)

  • Patients with Parkinson’s disease and psychosis have altered structural connectivity of the executive and visual networks

    P. Pal, A. Lenka, M. Ingalhalikar, A. Shah, J. Saini, S. Arumugham, S. Hegde, L. George, R. Yadav (Bangalore, India)

  • Patterns of dopamine transporter imaging in subtypes of Multiple System Atrophy

    F.T. Liu, L.L. Bu, Y.J. Yang, P. Wu, C.T. Zuo, J. Wang (Shanghai, China)

  • Patterns of Long-Term Custodial Care in Parkinson Disease Psychosis

    J. Wetmore, H. Yan, M. Irfan, A. Shim, Y. Peng, D. Gilbertson, S. Li (Minneapolis, MN, USA)

  • Patterns of rhythmic single unit activity of the subthalamic nucleus in patients with Parkinson’s disease

    E. Belova, A. Nezvinskiy, R. Medvednik, A. Tomskiy, A. Sedov (Moscow, Russian Federation)

  • PBT434 prevents the accumulation of glial cell inclusions and insoluble alpha-synuclein in a mouse model of Multiple System Atrophy

    D. Finkelstein, P. Adlard, N. Stefanova, D. Stamler (Parkville, Vic, Australia)

  • PD associated with GBA and LRRK2 mutations: Genotype-phenotype correlation

    V. Livneh, G. Yahalom, L. Greenbaum, S. Israeli-Korn, T. Fay-Karmon, S. Hassin, Z. Gan Or (Ramat Gan, Israel)

  • Peculiarities of Opsoclonus-Myoclonus Syndrome in India: A Systematic Review of reported cases

    J. Sahu, S. Negi (Chandigarh, India)

  • Pediatric Tics and DCD: Motor Network Disorders?

    M. Kuiper, R. Brandsma, W. Eggink, M. Egmond, J. de Vries, P. Hoekstra, A. Dietrich, D. Sival (Groningen, Netherlands)

  • People with PD have significantly impaired lower limb force production in all muscle groups: A cross sectional study

    E. Preston, R. Salmon, N. Mahendran, A. Flynn (Canberra, Australia)

  • Perceived Psychosocial Impacts of a Therapeutic Yoga Intervention for Individuals with Parkinson’s Disease (PD)

    B. Hawkins, M. Van Puymbroeck, A. Walter, K. Woschkolup, E. Urrea-Mendoza, F. Revilla, A. Schmid (Clemson, SC, USA)

  • Performance of Parkinson´s disease cognitive scale rating scale (PD-CRS) after subthalamic nucleus deep brain stimulation. Comparison with Mattis Dementia Rating Scale (MDRS) and Mini-Mental State Examination (MMSE)

    C. García-Sánchez, B. Pascual-Sedano, A. Gironell, R. Rodriguez, J. Pagonabarraga-Mora, J. Marin-Lahoz, J. Pérez-Perez, A. Campolongo, C. izquierdo, H. Bejr-Kasen, I. Aracil, S. Martínez -Horta, A. Horta, M. Botí, E. Marin, J. Kulisevsky (Barcelona, Spain)

  • Peripheral immune activation was associated with multiple system atrophy

    B. Cao, XP. Chen, WH. Feng, QQ. Wei, LY. Zhang, HF. Shang (Chengdu, China)

  • Peripheral Inflammatory Mediators in Parkinson’s Disease – A Potential Biomarker

    K. Chatterjee, A. Roy, R. Banerjee, S. Halder, S. Choudhury, P. Basu, S. Shubham, H. Kumar (Kolkata, India)

  • Peripheral nerve grafts implanted into the substantia nigra in patients with Parkinson’s disease during deep brain stimulation surgery: 2-year follow-up study of gait parameters

    Z. Guduru, G. Gera, G. Quintero, C. Van Horne, G. Gerhardt (Lexington, KY, USA)

  • Peripheral trauma elicits a dystonic phenotype in a DYT1 transgenic mouse model

    A. Stengl, L. Rauschenberger, S. Knorr, K. Grundmann, J. Volkmann, C. Ip (Wuerzburg, Germany)

  • Perry syndrome: Proposal of international diagnostic criteria and a new disease concept

    T. Mishima, S. Fujioka, H. Tomiyama, I. Yabe, R. Kurisaki, N. Fujii, R. Neshige, O. Ross, M. Farrer, D. Dickson, Z. Wszolek, N. Hattori, Y. Tsuboi (Fukuoka, Japan)

  • Persistent downbeat nystagmus due to Arnold-Chiari type I malformation

    W. Chen, L. Zhao, Q. He, L. Wu, R. Dong (Shanghai, China)

  • Personal KinetiGraph™ Movement Recording System: An Assessment of Utility in a Movement Disorder Clinic

    F. Nahab, H. Abuhussain, L. Moreno (La Jolla, CA, USA)

  • Personality Traits and Sleep Quality in Parkinson’s disease patients

    JY. Yun, HJ. Kim, HN. Kim, HL. Kim (Seoul, Republic of Korea)

  • Pharmacological investigation of biochemical and behavioral effects resembling Huntington’s disease utilizing selective calcium and calmodulin dependent phosphodiesterase inhibitor

    R. Mishra (Baddi, India)

  • Pharmacological modulation of lysosomal glucocerebrosidase activity in the Thy1-aSYN mouse model of Parkinson’s disease

    K. Belarbi, E. Cuvelier, H. Carrie, M.A. Bonte, W. Sibran, C. Leghay, J. Von Gerichten, V. Nordström, R. Sandhoff, T. Comptdaer, N. Jouy, E. Mutez, A. Destee, C. Pincon, B. Gressier, M.C. Chartier-Harlin (Lille, France)

  • Phase-locked transcranial alternating current stimulation of the cerebellum for essential tremor

    S. Schreglmann, D. Wang, E. Boyden, K. Bhatia, J. Rothwell, N. Grossman (London, United Kingdom)

  • Phenomenology and management of subthalamic stimulation-induced dyskinesia in a video case series of patients with isolated dystonia

    K. Dodenhoff, I. Bledsoe, M. San Luciano, M. Volz, L. Markun, P. Starr, J. Ostrem (San Francisco, CA, USA)

  • Phenotypic Heterogeneity and Variability of Nigrostriatal Dopaminergic Function in a Dopa-Responsive Dystonia

    J.J. Lin (Nantou, Taiwan)

  • Phenotypic variability of essential tremor based on the age at onset

    S. Prasad, A. Lenka, K. Jhunjhunwala, K. Bhalsing, P. Pal (Bengaluru, India)

  • Physical activity in people with Parkinson’s disease: A qualitative study

    J. McGinley, M. Danoudis, B. BIlney, M. Morris, R. Higgins (Parkville, Australia)

  • Physiological effects of Botulinum Toxin therapy in Primary Cervical Dystonia

    W. Deeb, W. Hu, A. Wagle Shukla (Gainesville, FL, USA)

  • Pilot economic evaluation of Personal KinetiGraph (PKG) for management of Parkinson’s disease in Australia

    P. Lynch, D. Jackson, D. Tilden, M. Horne (Minnetonka, MN, USA)

  • Pilot study of a new tool to optimize dopaminergic treatment in Parkinson’s disease: The OPTIPARK Scale Project

    J. Máñez Miró, F. Vivancos-Matellano, P. Martínez-Martín (Mostoles, Spain)

  • Pilot trial of botulinum toxin and occupational therapy for Writer’s Cramp

    J. Park, E. Shamim, O. Panyakaew, P. Mathew, C. Toro, J. Sackett, B. Karp, C. Lungu, K. Alter, B. Hodsdon, M. Villegas, T. Wu, O. Ahmad, P. Srivanitchapoom, S. Auh, M. (Goyang, Republic of Korea)

  • Pimavanserin Combined With Anti-Dementia Medications for Parkinson Disease Psychosis

    A. Espay, M. Guskey, N. Larsen, B. Coate, J. Vizcarra, S. Factor, J. Friedman, D. Weintraub, A. Lang (Cincinnati, OH, USA)

  • Pisa syndrome in Parkinson’s disease: Evidence for bilateral vestibulospinal dysfunction

    G. Di Lazzaro, T. Schirinzi, S. Di Girolamo, R. Di Mauro, A. Pisani (Rome, Italy)

  • PLA2G6-related juvenile-onset Parkinsonism: clinical features and cognitive profile in a cohort of Chinese patients

    C. Chen, Y.M. Sun, F.T. Liu, S.S. Luo, Z.T. Ding, J.J. Wu, J. Wang (Shanghai, China)

  • Plasma levels of vitamin D in patients with Parkinson’s disease: Correlation with Mini Mental State Examination and disease duration

    M. Barichella, L. Lorio, C. Bolliri, A. Giana, V. Ferri, G. Pinelli, E. Cassani, S. Caronni, C. Esposito, G. Riboldazzi, A. Maras, A. Perretti, F. Del Sorbo, P. Amadeo, R. Cilia, E. Cereda, G. Pezzoli (Milan, Italy)

  • Plasma transferrin level correlates with the tremor-dominant phenotype of Parkinson’s disease

    S. Qian, Y. Sheng, Z. Zhong (Nanjing, China)

  • PLG restores the balance of autophagy and apoptosis by increasing BCL2 phosphorylation in rotenone-induced Parkinson disease models

    J. Liu, H. Yang (Beijing, China)

  • Polymorphisms of glutamatergic system genes are associated with levodopa-induced dyskinesia in Parkinson’s disease

    I. Mironova, A. Latypova, I. Zhukova, O. Izhboldina, E. Kolupaeva, N. Zhukova, S. Ivanova (Tomsk, Russian Federation)

  • Polysomnographic data in Dementia with Lewy Bodies: Correlation with clinical features and comparison with other alfa-synucleinopathies

    P. Bugalho, M. Salavisa, J. Marto, C. Borbinha, L. Alves (Lisbon, Portugal)

  • Poor responders to STN DBS in Parkinson’s disease: 1 year follow-up study

    M. Zibetti, L. Ricciardi, E. Montanaro, M. Sarchioto, M. Edwards, L. Lopiano, F. Morgante (Toriino, Italy)

  • Possible neurotoxic hazards of common adulterants in Tea among Drosophila; ascertainment of toxicity of Tea preparations from local shops of an Indian city

    C. Ratnakaran, G. Chandran (Bengaluru, India)

  • Post-Deep Brain Stimulation Psychosis in Parkinson’s Disease: A Meta-analysis

    YC. Tai, N. Mahant, B. Stubbs, A. Carvalho, YW. Chen, TY. Chen, SP. Hsu, PT. Tseng (Kaohsiung, Taiwan)

  • Postural deformities in Chinese patients with multiple system atrophy

    L. Zhang, B. Cao, Y. Zou, Q. Wei, R. Ou, B. Zhao, J. Yang, Y. Wu, H. Shanng (Chengdu, China)

  • Postural Stability in Blepharospasm and the Effects of Botulinum Toxin Therapy

    M. Balal, T. Demir, M. Erdem, M. Demirkiran (Adana, Turkey)

  • Postural Sway Complexity as a Measure of Motor Functionality in Fragile X Premutation Carriers

    C. O'Keeffe, L. Taboada, N. Feerick, L. Gallagher, T. Lynch, R. Reilly (Dublin, Ireland)

  • Potential indicator of antiparkinsonian drug efficacy: an attempt to explore imaging findings

    S. Taguchi, N. Tanabe, H. Oiwa, M. Hayashi, C. Nagatomi, S. Saeki, K. Nakashima, T. Yuasa, A. Yasumoto, H. Ando, T. Higa, A. Fujikake, T. Fukuoka, K. TokuI, Y. Okada, J. Niwa, M. Izumi, N. Nakao, M. Doyu (Nagakute, Japan)

  • PPMI driven sample size estimation for clinical trials in Parkinson’s disease

    K. Marek, J. Seibyl, C. Caspell-Garcia, C. Coffey, B. Mollenhauer, K. Kieburtz, C. Tanner, L. Chahine, A. Siderowf, T. Simuni (New Haven, CT, USA)

  • Practice patterns, motor outcomes and health disparities in patients undergoing Deep Brain Stimulation for Parkinson’s disease

    C. Luca, D. Garbin diLuca, H. Moore, C. Singer, I. Cajigas, J. Jagid (Miami, FL, USA)

  • Prayer Dancing Dystonia: A Novel Form of Non-Occupational Task Specific Focal Dystonia

    L. Jaffe (Honolulu, HI, USA)

  • Pre-supplementary Motor Area Contributes to Motor Aspects of Sequential Risk-Taking

    A. Lohse, D. Meder, A. Løkkegaard, H. Siebner (Hvidovre, Denmark)

  • Preclinical cardiovascular sympathoexcitatory effects of TD-9855, a novel norepinephrine transporter (NET) inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with primary autonomic failure

    S. Hegde, M. Pulido-Rios, A. McNamara, J. Smith, W. Smith, J. Kanodia, D. Bourdet (South San Francisco, CA, USA)

  • Preclinical evaluation of a novel autologous substrate for cell-based therapy

    S. Benoit, H. Xu, J. Ronald, P. Foster, S. Schmid, M. Hebb (London, ON, Canada)

  • Predicting Alpha-Synuclein Pathology by REM Sleep Behavior Disorder Diagnosis

    D. Shprecher, C. Adler, N. Zhang, J. Hentz, G. Serrano, B. Dugger, H. Shill, R. Savica, J. Caviness, M. Sabbagh, C. Belden, E. Driver-Dunckley, S. Mehta, L. Sue, K. Davis, E. Zamrini, T. Beach (Sun City, AZ, USA)

  • Predicting patient risk and discharge disposition subsequent to deep brain stimulation surgery

    F. Farrokhi (Seattle, WA, USA)

  • Prediction of suicidality in Huntington disease: Analysis of Enroll-HD data using machine learning approach

    Y. Seliverstov, A. Borzov, E. van Duijn, B. Landwehrmeyer, M. Belyaev (Moscow, Russian Federation)

  • Predictive factors of fast cognitive decline in Parkinson’s disease after subthalamic stimulation: Myth or reality?

    F. Fluchere, F. Ory-Magne, M. Anheim, V. Rousseau, A. Eusebio, O. Lagha Boukbiza, B. Lemesle, T. Witjas, N. Longato, C. Tranchant, C. Brefel-Courbon, JP. Azulay (Marseille, France)

  • Predictive factors of quality of life evolution in Parkinson’s disease patients participating in a therapeutic patient education program

    C. Derollez, N. Carriere, D. Haidon, M. Kyheng, S. Peres, L. Defebvre (Lille, France)

  • Predictor for speech deterioration following STN-DBS in PD patients

    Y. Tanaka, T. Tsuboi, H. Watanabe, D. Nakatsubo, S. Maesawa, S. Kato, Y. Kajita, M. Sato, R. Odake, M. Hattori, M. Yamamoto, T. Wakabayashi, M. Katsuno, G. Sobue (Nagoya, Japan)

  • Predictors and biomarkers of pain in newly diagnosed Parkinson’s disease patients during a two-year follow-up

    S. Perez-Lloret, A. Sauerbier, C. Falup-Percurariu, M. Tinazzi, K.R. Chaudhuri (Buenos Aires, Argentina)

  • Predictors of alcohol responsiveness in dystonia

    J. Junker, V. Brandt, B. Berman, M. Vidailhet, E. Roze, A. Weissbach, C. Comella, I. Malaty, J. Jankovic, M. LeDoux, A. Berardelli, R. Barbano, S. Reich, J. Perlmutter, H. Jinnah, N. Brueggemann (Luebeck, Germany)

  • Predictors of freezing of gait in newly diagnosed Parkinson’s disease: Clinical, dopamine transporter imaging and CSF markers in the PPMI cohort

    R. Kim, J. Lee, H.J. Kim, A. Kim, B. Jeon, U.J. Kang, S. Fahn (Seoul, Republic of Korea)

  • Predictors of health-related quality of life in Parkinson’s disease

    G. Kuhlman, M. Barrett, J. Flanigan (Charlottesville, VA, USA)

  • Prefrontal cortical stimulation to treat anxiety and depression in Parkinson’s disease

    C. de Hemptinne, W. Chen, C. Racine, A. Seritan, A. Miller, J. Mergenthaler, S. Rajagopalan, J. Ostrem, M. San Luciano, P. Starr (San Francisco, CA, USA)

  • Preliminary evaluation of the Integrated Parkinson’s Care Network (IPCN): An integrated care model for complex needs

    T. Mestre, D. Kessler, D. Coté, K. Thavorn, C. Liddy, M. Taljaard, D. Grimes (Ottawa, ON, Canada)

  • Preliminary evidence for an altered relationship between uric acid levels and resting state functional connectivity in REM sleep behavior disorder

    M. Schiess, J. Suescun, L. Giancardo, R. Castriotta, T. Ellmore (Houston, TX, USA)

  • Preliminary Results of Psychometric Properties of the Freezing of Gait Questionnaire in Turkish Patients with Parkinson’s Disease

    E A. Ozturk, F. Nazli, B. Gonenli Kocer, S B. Tonuk, A. Can, N. Tezel, C. Uz, O. Ecerkale, F A. Cakci (Ankara, Turkey)

  • Preliminary Results of Psychometric Properties of the Turkish version of Falls Efficacy Scale – International in Patients with Parkinson’s Disease

    F. Nazli, E A. Ozturk, B. Gonenli Kocer, S B. Tonuk, N. Tezel, A. Can, C. Uz, O. Ecerkale, F A. Cakci (Ankara, Turkey)

  • Preliminary Study of Depression in Parkinson’s Disease with Diffusion Tensor Imaging

    C. Dejie, S. QuanXi, C. Shihuo (Yunfu, Guangdong, China)

  • Presence of Lewy dots in the brain of patients with Creutzfeldt-Jakob disease

    R. Valenti-Azcarate, I. Martinez-Valbuena, M. Tuñon-Alvarez, I. Marcilla-Garcia, L. Alonso-Herrero, M. Carmona-Abellan, G. Marti-Andres, E. Erro-Aguirre, M. Luquin-Piudo (Pamplona, Spain)

  • Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson’s disease

    HS. Yoo, SJ. Chung, BS. Ye, YH. Sohn, PH. Lee (Seoul, Republic of Korea)

  • Prevalence and associations for depression in patients with Parkinson’s disease: A Sri Lankan experience

    T. Herath, C. Rodrigo, M. Withana (Colombo, Sri Lanka)

  • Prevalence and characteristics of patients with progressive supranuclear palsy (PSP) in US health insurance claims data

    E. Viscidi, T. Dam, M. Juneja, L. Li, H. Krzywy, S. Eaton, S. Chen, S. Hall, A. Dilley (Cambridge, MA, USA)

  • Prevalence and Correlates of Anxiety & Depression in Cervical Dystonia

    M. Al Hussona, I. Ndukwe, S. O'Riordan, R. Beck, R. Reilly, M. Hutchinson (Dublin, Ireland)

  • Prevalence and influence of co-pathologies in patients with autopsy-confirmed Lewy body disorders: A systematic review

    D. Breen, E. Ravid, A. Lang, J. Miyasaki, R. Camicioli (Toronto, ON, Canada)

  • Prevalence and predictors of mood and health-related quality of life impairment among patients with parkinson’s in sub-saharan neurology clinic

    U. Williams, S. Oparah, H. Okpa (Calabar, Nigeria)

  • Prevalence and relationship of non-motor symptoms of Parkinson’s disease with plasma uric levels

    Y. Zubair, S. Oyakhire, S. Abdulrahaman, O. Medu, S. Bwala (Abuja, Nigeria)

  • Prevalence and risk factor of peak-dose dyskinesia in Thai patients with Parkinson’s disease

    S. Klanbut, C. Luangsinsiri, N. Piyaparneekul, C. Khongbut, K. Methawasin (Nakhon Nayok, Thailand)

  • Prevalence and risk factors for visual hallucinations in Chinese patients with Parkinson’s disease

    J. Zhu, L. Zhang (Nanjing, China)

  • Prevalence of Autonomic dysfunction and its correlation with Clinico-imageological features in Parkinson’s Disease

    R. Borgohain, S. Turaga, R. Kandadai, S. Tandra, M. Katragadda, S. Meka, T. Syed (Hyderabad, India)

  • Prevalence of focal task specific lower extremity dystonia symptoms in runners

    R. Thompson, A. Hellman, D. Torres-Russotto (Lebanon, NH, USA)

  • Prevalence of non-motor symptoms in Parkinson’s disease and its impact on quality of life in a tertiary care center in India

    M. Karri, B. Ramasamy, R. Kalidoss (Coimbatore, India)

  • Prevalence of Patient-Reported Symptoms of Dysphonia and Dysphagia in Movement Disorder Patients at an Academic Medical Center

    M. Finger, M. Siddiqui, J. Tate, I. Haq, L. Madden (Winston-Salem, NC, USA)

  • Prevalence of REM sleep behavior disorder and sleep-disordered breathing in multiple system atrophy: A meta-analysis

    SL. Wu, CS. Chuang (Changhua, Taiwan)

  • Prevalence of REM Sleep Behavior Disorder in Sun City, Arizona

    D. Shprecher, A. Intorcia, M. Glass, J. Curry, J. Walker, B. Cutler, M. Callan, G. Serrano, N. Zhang, L. Sue, K. Davis, T. Beach (Sun City, AZ, USA)

  • Prevalence of Single Nucleotide Polymorphisms (SNPs) rs362307 or rs362331 in Patients with Huntington’s Disease

    S. Hung, D. Claassen, M. Edmondson, R. Reilmann, N. Svrzikapa, K. Longo, J. Goyal, M. Panzara (Cambridge, MA, USA)

  • Prevalence, Distribution and Management of Parkinson among Pakistani Population

    S. Naureen (Rawalpindi, Pakistan)

  • Prevelance in the World

    Tur. Djakhangir (Tashkent, Uzbekistan)

  • Primary familial brain calcification – The impact of calcifications on the development of motor symptoms

    D. Alvarez-Fischer, C. Schiemenz, G. Mahlke, A. Keller, A. Westenberger, J. Erdmann, Z. Aherrahrou, C. Klein (Lübeck, Germany)

  • Probable MSA presenting initially with urinary retention

    S. Simeoni, R. Sakakibara, J. Panicker (London, United Kingdom)

  • Prodromal features of Parkinson’s disease in women

    K. Hughes, X. Gao, J. Baker, C. Stephen, I. Kim, L. Valeri, M. Schwarzschild, A. Ascherio (Boston, MA, USA)

  • Profiles of microRNA in cerebrospinal fluid could be potential biomarkers for identifying motor subtype of Parkinson’s disease

    W. Jang (Gangneung, Republic of Korea)

  • Programming for Freezing of gait after Bilateral Subthalamic Nucleus Deep Brain Stimulation for Parkinson’s Disease

    H. Zheng, F. Sun, L. Zhang (Nanjing, China)

  • Progression of sleep disorders spectrum in Parkinson’s Disease: A 5 year clinical longitudinal study

  • Progressive encephalomyelitis with rigidity and myoclonus (PERM): Phenomenology, investigations and management of two recent cases

    T. Munteanu, Y. LLamas-Osorio, P. Cullinane, T. Lynch (Dublin, Ireland)

  • Progressive Supranuclear Palsy and Eye of the Tiger Sign

    O. Dogu, H. Genç, N. Öksüz (Mersin, Turkey)

  • PROMESA: A randomised, double-blind, placebo-controlled trial to evaluate the progression rate of MSA under EGCG supplementation as anti-aggregation-approach

    J. Levin, S. Maass, M. Schuberth, A. Giese, W. Oertel, W. Poewe, C. Trenkwalder, G. Wenning, U. Mansmann, M. Suedmeyer, K. Eggert, B. Mollenhauer, A. Lipp, M. Loehle, J. Classen, A. Muenchau, J. Kassubeck, G. Ebersbach, D. Berg, S. Egert, C. Eberhardt, F. Paul, K. Boetzel, B. Ertl-Wagner, H. Huppertz, I. Ricard, G. Hoeglinger (Munich, Germany)

  • Pronounced synucleinopathy and nigrostriatal degeneration result in forelimb use deficits in the rat preformed alpha-synuclein fibril model

    J. Patterson, M. Duffy, T. Collier, K. Luk, C. Kemp, J. Howe, P. Patel, A. Stoll, K. Miller, N. Kanaan, K. Paumier, C. Sortwell (Grand Rapids, MI, USA)

  • Proof-of-Principle Quantitative EEG Study of CX-8998, an Oral, Potent and Selective T-Type Calcium antagonist in development for symptomatic treatment of Essential Tremor and Parkinson’s disease Tremor

    S. Papapetropoulos, M. Lee, S. Boyer (Cambridge, MA, USA)

  • Properties of oscillatory neuronal activity in the basal ganglia and thalamus in patients with Parkinson’s disease

    P. Zhuang, M. Hallett, G. Du, Y. Zhang, Y. Li (Beijing, China)

  • Propionibacterium acnes Infection with Intracerebral Abscess in Deep Brain Stimulation

    R. Lewis, F. Farrokhi, M. Marsans (Seattle, WA, USA)

  • Propofol-induced acute dystonic reaction after orthopedic surgery in a young healthy woman

    R. Barbosa, M. Salavisa, M. Mendonça (Lisbon, Portugal)

  • Propranolol Induced Visual Hallucinations: A Case Report Charles Bonnets Syndrome in Parkinson Disease

    M. Şenol, M. Kendirli (Istanbul, Turkey)

  • Prospective, home-based assessment of motor symptoms in Parkinson’s disease by mean of the Sleep Fit app: A potential new clinical approach

    P-L. Ratti, F. Faraci, A. Mascheroni, S. Hackethal, C. Ferlito, S. Caverzasio, E-K. Choe, Y. Luo, P-E. Nunes Ferreira, A. Puiatti, A. Kaelin-Lang (Lugano, Switzerland)

  • Protective effects of Mucuna pruriens seed on rat brain: A therapeutic potential drug for Parkinson’s disease

    S. Rajput, S. Sinha (New Delhi, India)

  • PROtein, LEucine And vitamin D Enhancing Rehabilitation (PRO-LEADER) in patients with Parkinson’s disease or parkinsonism: A RCT

    M. Barichella, E. Cereda, G. Pinelli, L. Iorio, D. Caroli, I. Masiero, V. Ferri, E. Cassani, C. Bolliri, S. Caronni, P. Ortelli, D. Ferrazzoli, A. Maras, G. Riboldazzi, G. Frazzitta, G. Pezzoli (Milano, Italy)

  • Proteomic analysis of tear-fluid reveals disease-specific patterns in patients with Parkinson’s Disease

    M. Börger, S. Funke, F. Maass, A. Leha, AE. Roser, AK. Wüstemann, M. Bähr, F. Grus, P. Lingor (Göttingen, Germany)

  • PrP as a receptor of alpha-synuclein in the pancreas of patients with synucleinopathies

    I. Martinez-Valbuena (Pamplona, Spain)

  • Psychogenic Palatal Tremor: A Case Report

    A. Tüfekçi, Ç. Hocaoğlu, D. Yanoğlu, K.S. Karataş (Rize, Turkey)

  • Psychosocial Impact of dysarthria: Is speech intelligibility an effective measure outcome?

    C. Atkinson-Clement, A. Letanneux, M. Berthelot, D. Robert, C. Robieux, C. Moreau, G. Baille, A. Eusebio, F. Fluchère, E. Robin, T. Witjas, J.P. Azulay (Aix-en-Provence, France)

  • PTRHD1 loss-of-function mutation in an African family with parkinsonism and intellectual disability

    IJcken, M. van Slegtenhorst, V. Bonifati (Rotterdam, Netherlands)

  • Public Awareness on Parkinson’s disease in Urban Central Asia

    O. Turgunkhujaev, F. Aliyeva, A. Khashimova, A. Mukanova, O. Okhunov, S.H. Ikramova, A.H. Tan, S.Y. Lim (Moscow, Russian Federation)

  • Pulvinar low intensity on susceptibility-weighted imaging may predict cognitive worsening after deep brain stimulation therapy in Parkinson’s disease patients

    K. Matsuura, M. Maeda, M. Satoh, K. Tabei, T. Araki, M. Umino, H. Kajikawa, N. Nakamura, H. Tomimoto (Tsu, Mie, Japan)

  • Pupil evaluation as the test for the clinical manifestations of Parkinson’s disease

    T. Araga, M. Shiraishi, K. Shinohara, Y. Hasegawa (Kawasaki, Japan)

  • Pupillary autonomic dysfunction and oculomotor characteristics of multiple system atrophy

    K.W. Park, EJ. Lee, N.R. Choi, M.S. Kim, S.J. Chung (Seoul, Republic of Korea)

  • Putaminal dopamine depletion in de novo Parkinson’s disease predicts future development of wearing-off

    S.J. Chung, Y. Lee, J.S. Oh, J.S. Kim, P.H. Lee, Y.H. Sohn (Goyang, Republic of Korea)

  • Putative treatment of Parkinson’s Disease using extract of Bacopa monnieri

    S. Sinha, P. Kumar (Allahabad, India)

Jump to:  View All • a b c d e f g h i j k l m n o [p] q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley